Abst0369 #acr2021 @rheumnow #acrbest ⬆️ level of pregnancy complications in axSpA in Irish registry. 41.9% complicated, 11.4% pregnan w/multiple complications. Miscarriage 20.5%. Amongst live births 10.8% c-section, preterm 11.4% . NICU admiss11.4%. ⬇️ breastfeeding rate at 33.7% https://t.co/plF8fykCKT

KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such. @RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm

RELIANCE interim data shows efficacy & safety of long-term CAN in FMF. This observational study is a good start, but offers questions regarding dosing of CAN in this patient population. Abs 0192 #ACR21 #RheumNow @RheumNow https://t.co/46o7AnUVj2 https://t.co/7oAPovbukl

• Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment i…

Pain in #spondyloarthritis is complex and multifactorial. Study of nearly 3000 patients, higher pain intensity was associated with working life impairment, spinal stiffness, education, gender, depression, anxiety and sleep @RheumNow, #ACR21 and Abst#0360 https://t.co/xEVI4L0Chw

• Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from…

#ACR21 Abst#0289: Predictive score for preclinical RA-ILD based on 4 identified RF: ⭐︎ ⚦ sex (OR 3.9) ⭐︎ MUC5B T-risk allele (OR 3.7) ⭐︎ mean DAS-28 (OR 2.0) ⭐︎ older age at RA onset (1.1) Obtain HRCT if w/ above (Se ~87%)! #ACRBest @Rheumnow https://t.co/KKRkQVY2pf https://t.co/wifiTi6vPq

• Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients…

RELIANCE interim data shows that long-term CAN is safe & effective in CAPS. Interestingly, investigators observed a trend toward updosing over standard dosing. Abs 0191 #ACR21 #RheumNow @RheumNow https://t.co/ik6dAEZjFf https://t.co/arqSEzuC6Q

• Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients wi…

Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy. Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions. What would you choose? #ACR21 #ACRBest @RheumNow https://t.co/FywUp3zCj2

Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi

@jhrheumatology Dr. Petri - if Lupus nephritis biopsy is very active start a dual therapy with MMF right away. ▶️ If not, continue to re-evaluate at 3 and 6 months for early combo therapy #ACR21 Great Debate @Rheumnow https://t.co/ctKdbWTMqy

How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination? Better chance of response if: - RA or SLE, not AAV or IIM - high serum IgG pre-last RTX - longer time since last RTX Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6

Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6

#ACR21 Great Debate: Voclosporin vs Tacro? ⭐️Voclosporin has carbon bond extension, changing how voclosporin binds to calcineurin. ⭐️Consistent dose-response prevents need for drug monitoring ⭐️Increases potency and results in improved metabolic profile @Rheumnow https://t.co/cY93st7754

This is an important slide showing how belimumab protected the GFR... ultimately the reason why we are treating #lupus nephritis patients - Prof Michelle Petri @RheumNow #ACR21 #rheumatology 📌https://t.co/bO3ubqY2bf https://t.co/yuqwlKXDBH

• https://bit.ly/3o73kKC

#ACR21 Abs#0101 on recombinant #zoster vaccine (RZV) in #IMIDs: •High proportion of ≥50yos w/ IMIDs received RZV but 15–25% did not get 2nd dose within 6m •#Vaccination higher in ≥65yos than 50–64yos •Need better vaccine policy to encourage uptake in pts w/ IMIDs @RheumNow https://t.co/i5JDJClTyQ